{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:05:15Z","timestamp":1783699515699,"version":"3.55.0"},"reference-count":31,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Zai Laboratories"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>Omadacycline is a derivative of minocycline and the first agent of the aminomethylcycline class. A total of 3,282 organisms (1 per patient) were consecutively collected from patients hospitalized in China (including Hong Kong) and Taiwan.<\/jats:p>","DOI":"10.1128\/aac.02262-18","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T12:33:27Z","timestamp":1546950807000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":30,"title":["Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016)"],"prefix":"10.1128","volume":"63","author":[{"given":"Cecilia G.","family":"Carvalhaes","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald H.","family":"Reinhart","sequence":"additional","affiliation":[{"name":"Zai Lab (Shanghai) Co., Ltd., Pudong, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","volume-title":"World population prospects: the 2017 revision, key findings and advance tables","author":"Department of Economic and Social Affairs","year":"2017","unstructured":"Department of Economic and Social Affairs. 2017. World population prospects: the 2017 revision, key findings and advance tables. United Nations, New York, NY. https:\/\/population.un.org\/wpp\/Publications\/Files\/WPP2017_KeyFindings.pdf."},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12705"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2012.07.009"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2011.07.001"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2015.02.001"},{"key":"e_1_3_2_7_2","volume-title":"Review on antimicrobial resistance. antimicrobial resistance: tackling a crisis for the health and wealth of nations","author":"O\u2019Neill J","year":"2014","unstructured":"O\u2019Neill J 2014. Review on antimicrobial resistance. antimicrobial resistance: tackling a crisis for the health and wealth of nations. HM Government, London, United Kingdom. https:\/\/amr-review.org\/sites\/default\/files\/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2016-0100"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.19.2.382-402.2006"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-009-0172-6"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00018-17"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23872"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00948-12"},{"key":"e_1_3_2_14_2","volume-title":"Omadacycline for acute bacterial skin and skin structure infections: Integrated analysis of randomized clinical trials","author":"Abrahamian FM","year":"2018","unstructured":"Abrahamian FM, Sakoulas G, Tzanis E, Manley A, Steenbergen JN, Das A, Eckburg P, McGovern P. 2018. Omadacycline for acute bacterial skin and skin structure infections: Integrated analysis of randomized clinical trials, abstr 1347. ID Week, October 3\u20137, San Francisco, CA."},{"key":"e_1_3_2_15_2","volume-title":"Omadacycline versus moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia (CABP): efficacy analysis according to EMA requirements","author":"Torres A","year":"2018","unstructured":"Torres A, Garrity-Ryan L, Kirsch C, Steenbergen J, Eckburg P, Das A, Manley A, Tzanis E, McGovern P. 2018. Omadacycline versus moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia (CABP): efficacy analysis according to EMA requirements, abstr P-0274. European Congress for Clinical Microbiology and Infectious Diseases (ECCMID), April 21\u201324, Madrid, Spain."},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2015.8"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02327-17"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02411-16"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.10.010"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2013.07.003"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgar.2017.10.018"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2018.01.019"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01288-13"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2018.01.006"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01135-17"},{"key":"e_1_3_2_26_2","volume-title":"M07Ed11E. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. M07Ed11E. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 11th ed. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"11"},{"key":"e_1_3_2_27_2","volume-title":"M100Ed28E. Performance standards for antimicrobial susceptibility testing, 28th informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. M100Ed28E. Performance standards for antimicrobial susceptibility testing, 28th informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_28_2","volume-title":"Breakpoint tables for interpretation of MIC's and zone diameters","author":"EUCAST","year":"2018","unstructured":"EUCAST. 2018. Breakpoint tables for interpretation of MIC's and zone diameters, version 8.0, January 2018. EUCAST, V\u00e4xj\u00f6, Sweden. http:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_8.0_Breakpoint_Tables.pdf."},{"key":"e_1_3_2_29_2","volume-title":"Recognized antimicrobial susceptibility test interpretive criteria for omadacycline","author":"FDA","year":"2018","unstructured":"FDA. 2018. Recognized antimicrobial susceptibility test interpretive criteria for omadacycline. FDA, Silver Spring, MD. https:\/\/www.fda.gov\/Drugs\/DevelopmentApprovalProcess\/Developmentresources\/ucm622612.htm."},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2006.01377.x"},{"key":"e_1_3_2_31_2","volume-title":"MIC and zone diameter distributions and ECOFFs","author":"EUCAST","year":"2018","unstructured":"EUCAST. 2018. MIC and zone diameter distributions and ECOFFs. http:\/\/www.eucast.org\/mic_distributions_and_ecoffs\/."},{"key":"e_1_3_2_32_2","volume-title":"Tygacil package insert","author":"Tygacil","year":"2018","unstructured":"Tygacil. 2018. Tygacil package insert. Wyeth Pharmaceuticals LLC, Philadelphia, PA. http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?format=PDF&id=491."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02262-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02262-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:29:31Z","timestamp":1645478971000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02262-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1128\/AAC.02262-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.02262-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"2018-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02262-18"}}